Home About Us Writing a Scientific Article Author's Instruction Contact us



/  /    MRJMMS Home   /   /    About MRJMMS    /  /    Submit Manuscripts    /  /      Call For Articles      / /     Editorial Board     / /    Archive     / /    Author's Guide  /  /


April 2022 Vol. 10 No.4

Other viewing option

Full text
Reprint (PDF) (164 KB)

Search Pubmed for articles by:

Eldeeb SA
Soliman NA

Other links:
PubMed Citation
Related articles in PubMed


Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 10(4) pp. 115-124, April, 2022 

Copyright © 2022 Author(s) retain the copyright of this article
DOI: 10.5281/zenodo.6478609

Original Research Article

Immunohistochemical Expression of SATB2 and Clinicopathological Correlation in Colorectal Adenocarcinoma


Shorouk A. Eldeeb1, Mostafa M. Salem2, Deaa F. Morsi1 and Nahed A. Soliman1*


1Department of Pathology, Faculty of Medicine, Helwan University, Helwan 11795, Egypt;
2Department of Pathology, Faculty of Medicine, Cairo University, Cairo 12613, Egypt

*Corresponding Author's E-mail: nahed.soliman@med.Helwan.edu.eg, nahedram@yahoo.com
Mobile/ 00201000106964
Received: 28 March 2022  I  Accepted: 21 April 2022  I  Published: 25 April 2022  I  Article ID: MRJMMS22045
Copyright © 2022 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0.




Special AT-rich sequence-binding protein 2(SATB2) is a peculiar marker in the diagnosis of colorectal carcinoma (CRC), SATB2 has been employed as a colorectal differentiation marker with the potential to be useful in distinguishing the origin of adenocarcinomas of unknown primary origin. Also SATB2 inhibit colorectal cancer progression and low expression of SATB2 protein has been associated with low survival outcome. The aim of the study was to assess the SATB2 immunohistochemical expression in CRC, and association with several clinicopathological characteristics. Immunohistochemical staining for SATB2 was done on 70 cases of colorectal adenocarcinoma that underwent colectomy. Their expressions were analysed as negative, intermediate and strong then correlated to clinico-pathological parameters in an attempt to obtain the most significant predictors of SATB2. SATB2 score was negative in 30 %of the cases, intermediate in 54.3% and strong in 15.7%. Strong SATB2 expression was significantly associated with a low tumor histological grade (P = 0.007), a low tumor invasiveness stage (P = 0.001), the absence of lymph node metastasis (P = 0.001), the absence of detected distant metastasis (P = 0.039), a low TNM stage (P = 0.001), a low modified Dukes stage (P = 0.001), the absence of lympho-vascular invasion (P value 0.001) and the absence of perineural invasion (P = 0.001).A High rate of SATB2 expression was associated with left colon tumors and adenocarcinoma histological type, but without a statistically significant correlation. In the cases analyzed, there was no significant association between SATB2 expression and age, sex, or tumor size. Strong SATB2 expression is associated with the accepted clinicopathological parameters favoring good prognosis in the colorectal cancer and may represent a potential therapeutic target.

Keywords: Colorectal carcinoma, Immunohistochemistry, SATB2.















Merit Research Journals© 2022 || Advertisement | Privacy policy.